Biopharma’s 6 Biggest Deals: Were They Worth It?

With Amgen set to drop $10.4 billion on Onyx, investors are wondering how effective super-sized biopharma acquisitions are

      View All  
Biopharma’s 6 Biggest Deals: Were They Worth It?

Merck (Schering-Plough)

MerckLogo e1282588089406 Biopharmas 6 Biggest Deals: Were They Worth It?Remember when Merck (MRK) bought Schering-Plough for a cool $41.1 billion in 2009? Both were behemoths with wide drug menus, so Merck didn’t score any game-changing products. Rather, the two companies mostly sought to team up so they could take on competitors like Pfizer, which had acquired Wyeth earlier in the same year.

Truth be told, it wasn’t a bad deal. But it wasn’t necessarily a good deal either. Both organizations had a strong presence in cardiovascular and respiratory drugs, and decent pipelines.

The biggest value the union brought to the table was operational synergies, which at least somewhat materialized.


Article printed from InvestorPlace Media, http://investorplace.com/2013/08/did-biopharmas-biggest-ever-deals-pay-off/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.